CorMedix Inc

CRMDNASDAQ · USD
4.50USD-0.17 (-3.64%)
1012

CorMedix Inc (CRMD) Covered Calls

CorMedix Inc trades in the Biotechnology industry with an IV Rank of 51.19%, average versus the past year. CRMD's highest covered call setup is the $15.00 strike expiring Jan 21, 2028, sorted by theoretical annualized return. It's 221.89% out of the money with 434 days to expiration, a 224.03% return until expiration, and a 188.42% theoretical annualized return. Across the setups shown, annualized returns run from 10.21% to 188.42% at strikes between $5.00 and $15.00, with 126 to 798 days to expiration, as of Nov 13, 2026.

Read more

Running CRMD covered calls helps you generate income from CorMedix Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CRMD covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CRMD stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CRMD covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CRMD covered call is worth writing.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc.

2028-01-2143415.00221.890.101.601044.00224.03188.42-2.15+0.381781.50
2028-01-2143410.00114.590.300.65564.00121.03101.79-6.44+0.301,1340.35
2027-03-191266.0028.760.050.50139.0029.8386.41-1.07+0.312620.45
2027-06-172166.0028.760.401.25174.0037.3463.10-8.58+0.491340.85
2029-01-1979810.00114.590.055.00539.00115.6752.90-1.07+0.73264.95
2027-03-191265.007.300.401.1574.0015.8846.00-8.58+0.5540.75
2027-06-172165.007.300.053.1039.008.3714.14-1.07+0.66283.05
2029-01-197985.007.300.705.00104.0022.3210.21-15.02+0.81224.30

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank51.19% Moderate
  • Market cap (M$)371
  • 52 weeks high-64.13%
  • 52 weeks low0.43%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$13.80
    237.78% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-12
  • P/E7.10
  • Future P/E—
  • EPS (ttm)0.66
  • EPS growth next 5 years—

As of Nov 17, 2026